Associated Papers
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.
Diamond EL et al.
Cancer Cell, 2026
Concurrence of a kinase-dead BRAF and an oncogenic KRAS gain-of-function mutation in juvenile xanthogranuloma.
Seidel MG et al.
Pediatric Blood & Cancer, 2023
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Durham BH et al.
Nature Medicine, 2019
31768065 (PubMed )
Supplement: NIHMS1541330-supplement-1.pdf
Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
Shanmugam V et al.
Head and Neck Pathology, 2016
Select a paper to view details